Table 1.

Baseline characteristic and PRINTO core set measures at onset of the study population

	Group 1 (CR yes-TF no-PDN off) N = 30	Group 2 (CR no-TF no/PDN on or off)N = 43	Group 3 (CR no-TF yes/PDN on or off) N = 66	P *
Age at onset (years)	9.5 (6.2–12.3)	6.5 (3.3–9.8)	6.9 (4.2–10)	0.016
Disease duration (mo)	2.6 (1.3–4.7)	2.6 (1.3–6.4)	3.0 (1.5–4.8)	0.94
MD-global (0–10 ↑)	7.0 (6.0–8.0)	6.0 (5.0–7.0)	7.0 (5.0–8.0)	0.17
Parent global (0–10 ↑)	6.0 (5.0–8.0)	5.0 (3.5–7.0)	5.4 (5.0–7.0)	0.40
CHAQ (0–3 ↑)	1.8 (1.1–2.6)	1.8 (1.4–2.6)	1.9 (1.3–2.5)	0.94
DAS (0–20 ↑)	13.0 (11.0–15.0)	13.0 (11.0–15.0)	13.0 (11.0–15.0)	0.80
CMAS (0–52 ↓)	16.5 (13.0–33.0)	21.0 (14.0–35.0)	20.7 (11.0–32.0)	0.96
MMT (0–80 ↓)	40.0 (30.0–60.0)	47.0 (35.0–58.0)	48.0 (34.0–56.0)	0.84
CHQ PhS (40–60 ↓)	19.8 (9.4–33.4)	12.7 (5.2–23.5)	14.9 (8.1–22.4)	0.16

Data are medians (1st 3rdquartiles). *P: P value refers to the non-parametric Analysis of Variance (Kruskal-Wallis test); MD-global: physician’s global assessment of the patient’s overall disease activity on a 0–10-cm visual analogue scale (VAS); Parent global: parents’ global assessment of the child’s overall patient’s well-being on a 10-cm VAS; DAS Disease Activity Score; CMAS Childhood Myositis Assessment Scale, MMT manual muscle testing; CHAQ cross-culturally adapted and validated version of the Childhood Health Assessment Questionnaire); ↑ indicates that higher values correspond to a worse outcome; ↓ indicates that lower values correspond to a worse outcome